Cargando…

The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression

BACKGROUND: Migraine affects 1.1 billion people globally and is the second leading cause of disability worldwide. In clinical trials, treatment efficacy is evaluated by comparing the differential responses in the treatment and placebo arms. Although placebo response in preventive migraine trials has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tepper, Stewart J., Cirillo, Jessica, Kim, Edward, L’Italien, Gil, Tweedie, Julie M., Lodaya, Kunal, Riley, Dushon, Pathan, Farah, Antaki, Nicholas, Nathanson, Brian H., McAllister, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189936/ https://www.ncbi.nlm.nih.gov/pubmed/37193973 http://dx.doi.org/10.1186/s10194-023-01587-0

Ejemplares similares

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States
por: Harris, Linda, et al.
Publicado: (2021)

Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States
por: Harris, Linda, et al.
Publicado: (2022)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies
por: Harris, Linda, et al.
Publicado: (2023)

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
por: Johnston, Karissa, et al.
Publicado: (2022)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
por: Johnston, Karissa M., et al.
Publicado: (2021)

Measuring interictal burden among people affected by migraine: a descriptive survey study
por: Hubig, Lena T., et al.
Publicado: (2022)

Paracentral Acute Middle Maculopathy in Migraines with Aura
por: Milad, Daniel, et al.
Publicado: (2023)

A stated preference survey to explore patient preferences for novel preventive migraine treatments
por: Hubig, Lena T., et al.
Publicado: (2022)

Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
por: Lo, Siu Hing, et al.
Publicado: (2022)

Low-dose Ketamine Does Not Improve Migraine in the Emergency Department: A Randomized Placebo-controlled Trial
por: Etchison, Ashley R., et al.
Publicado: (2018)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022)

Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study
por: Sapra, Sandhya, et al.
Publicado: (2014)

Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: a Markov model simulation
por: Budd, David, et al.
Publicado: (2011)

Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary
por: Mathias, Susan, et al.
Publicado: (2013)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial
por: Lipton, Richard B, et al.
Publicado: (2021)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations: A Narrative Review
por: Ailani, Jessica, et al.
Publicado: (2022)

Review of patient-reported outcome measures in chronic hepatitis C
por: Kleinman, Leah, et al.
Publicado: (2012)

Migraine – the forgotten epidemic: development of the EHF/WHA Rome Declaration on Migraine
por: Diener, H.-C., et al.
Publicado: (2006)

Preventive treatment in migraine and the new US guidelines
por: Estemalik, E, et al.
Publicado: (2013)

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
por: Hanssens, Linda, et al.
Publicado: (2008)

Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life
por: Boscoe, Audra N., et al.
Publicado: (2019)

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
por: Ryan, Michael, et al.
Publicado: (2019)

The Hepatorenal Syndrome Patient Pathway: Retrospective Analysis of Electronic Health Records
por: Jamil, Khurram, et al.
Publicado: (2022)

CO142 Evaluating the Impact of the COVID-19 Pandemic on Acute Ischemic Stroke Outcomes in the Stroke Belt
por: Stitzlein, E., et al.
Publicado: (2023)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

Prophylaxis of migraine: general principles and patient acceptance
por: D’Amico, Domenico, et al.
Publicado: (2008)

Strategies of care for acute treatment of migraine
por: Tepper, Stewart J., et al.
Publicado: (2002)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2022)

C-MYC–induced Apoptosis in Polycystic Kidney Disease Is Bcl-2 and p53 Independent
por: Trudel, Marie, et al.
Publicado: (1997)

Reliability and Validity of the 6‐Minute Walk Test in Hypophosphatasia
por: Phillips, Dawn, et al.
Publicado: (2019)

Trends and Disparities in Firearm Fatalities in the United States, 1990-2021
por: Rees, Chris A., et al.
Publicado: (2022)

Lessons from placebo effects in migraine treatment
por: Antonaci, F., et al.
Publicado: (2007)

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine
por: Spierings, Egilius LH, et al.
Publicado: (2017)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura
por: Lipton, Richard B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fq0v6i16r37ulvs0d4d1bbahv2